Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
103 hedge funds and large institutions have $1.74B invested in Centessa Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 45 increasing their positions, 16 reducing their positions, and 8 closing their positions.
288% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 8
181% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 16
122% more capital invested
Capital invested by funds: $781M → $1.74B (+$956M)
29% more funds holding
Funds holding: 80 → 103 (+23)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7.92% more ownership
Funds ownership: 76.53% → 84.45% (+7.9%)
88% less call options, than puts
Call options by funds: $99K | Put options by funds: $848K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$33.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$28.8M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$26.1M |
| 4 |
CC
Commodore Capital
New York
|
+$16.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$30.5M |
| 2 |
AG
Artal Group
Luxembourg
|
-$19.1M |
| 3 |
Morgan Stanley
New York
|
-$8.22M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.49M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.19M |
CNTA Hedge Fund Activity: Q3 2024 in Review
103 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q3 2024, worth a combined $1.74B — up 122% from $781M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CNTA positions and 8 closed out — a net gain of 23 holders — while 45 added to existing stakes and 16 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $33.3M. The largest seller was EcoR1 Capital, cutting an estimated $30.5M.
- 103 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q3 2024, up from 80 in Q2 2024.
- Funds reported $1.74B of Centessa Pharmaceuticals stock for Q3 2024, up 122% quarter-over-quarter.
- 31 funds opened new Centessa Pharmaceuticals positions in Q3 2024 and 8 closed out, a net change of +23 holders.
- The largest Centessa Pharmaceuticals buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $33.3M added.
- The largest Centessa Pharmaceuticals seller in Q3 2024 was EcoR1 Capital, an estimated $30.5M sold.
Based on aggregated 13F filings for Q3 2024.